Quick-Med Technologies, Inc. (QMDT) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Quick-Med Technologies, Inc. (QMDT) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 57/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Quick-Med Technologies, Inc. (QMDT) Gesundheitswesen & Pipeline-Uebersicht
Quick-Med Technologies, Inc. operates in the specialty drug manufacturing sector, focusing on antimicrobial and hemostatic technologies. The company's NIMBUS, Stay Fresh, and MultiStat platforms target diverse applications in healthcare, textiles, and personal care, serving both government and commercial clients with specialized biomedical solutions.
Investmentthese
Quick-Med Technologies, Inc. presents a speculative investment opportunity within the specialty drug manufacturing sector. The company's proprietary NIMBUS, Stay Fresh, and MultiStat technologies offer potential for growth in diverse markets, including healthcare, textiles, and personal care. With a negative P/E ratio of -0.02 and a negative profit margin of -76.8%, the company's financial performance indicates it is not currently profitable. A gross margin of 69.8% suggests strong potential profitability if sales volume increases. Key catalysts include successful commercialization of their technologies and partnerships with larger industry players. However, the company's small size (5 employees) and OTC market listing introduce significant risks related to liquidity and operational scalability. The beta of -39.80 suggests an inverse correlation with the market, but this may be unreliable due to the company's limited trading volume.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross Margin of 69.8% indicates strong potential profitability if sales volume increases.
- Negative P/E ratio of -0.02 reflects current lack of profitability.
- Profit Margin of -76.8% indicates significant losses relative to revenue.
- The company has 5 employees, highlighting its small size and potential operational constraints.
- Beta of -39.80 suggests an inverse correlation with the market, but may be unreliable due to limited trading volume.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Potential for diverse applications in healthcare, textiles, and personal care.
- Existing relationships with government agencies.
- High gross margin (69.8%) indicates potential for profitability.
Schwaechen
- Small size and limited resources (5 employees).
- Negative profit margin (-76.8%) indicates significant losses.
- OTC market listing introduces liquidity and regulatory risks.
- Limited brand recognition and market presence.
Katalysatoren
- Upcoming: Potential FDA approval for new medical applications of NIMBUS technology (Timeline: 1-2 years).
- Ongoing: Expansion of licensing agreements for Stay Fresh formulation in the textile industry.
- Ongoing: Development of strategic partnerships with larger pharmaceutical companies for commercialization.
- Upcoming: Publication of clinical trial results for MultiStat technology in skin therapy (Timeline: 6-12 months).
Risiken
- Ongoing: Limited financial resources and negative profitability.
- Potential: Intense competition from larger pharmaceutical and healthcare companies.
- Potential: Stringent regulatory requirements and lengthy approval processes.
- Ongoing: OTC market listing introduces liquidity and regulatory risks.
- Potential: Dependence on key personnel and potential loss of intellectual property.
Wachstumschancen
- Expansion into the Healthcare Market: Quick-Med's NIMBUS technology, with its antimicrobial and hemostatic properties, can be further developed for wound care and surgical applications. The global wound care market is projected to reach $22 billion by 2028, presenting a significant opportunity for Quick-Med to capture market share through strategic partnerships and product innovation. Timeline: 2-3 years for product development and regulatory approvals.
- Penetration of the Textile Industry: The Stay Fresh formulation offers a durable antimicrobial solution for textiles, addressing the growing demand for hygienic and odor-resistant apparel. The global antimicrobial textiles market is estimated at $10 billion, with increasing adoption in sportswear, healthcare garments, and home textiles. Quick-Med can expand its market presence through collaborations with textile manufacturers and brands. Timeline: 1-2 years for partnership development and product integration.
- Development of Advanced Skin Therapy Products: The MultiStat technology can be leveraged to create innovative skin therapy products targeting various dermatological conditions. The global skin therapy market is projected to reach $40 billion by 2027, driven by increasing consumer awareness and demand for effective skincare solutions. Quick-Med can focus on developing niche products with unique formulations and clinical validation. Timeline: 2-3 years for product development and clinical trials.
- Strategic Partnerships with Government Agencies: Quick-Med can pursue collaborations with government agencies to develop and supply antimicrobial solutions for defense and public health applications. Government contracts offer stable revenue streams and opportunities for long-term growth. The company can leverage its NIMBUS technology to address specific needs in areas such as wound care and infection control. Timeline: Ongoing, with continuous engagement and proposal submissions.
- Licensing and Technology Transfer: Quick-Med can generate revenue by licensing its proprietary technologies to other companies in the healthcare, textile, and personal care industries. Licensing agreements provide a low-risk approach to expanding market reach and generating royalty income. The company can focus on identifying potential licensees with complementary capabilities and market access. Timeline: Ongoing, with continuous evaluation of licensing opportunities.
Chancen
- Expansion into the wound care market with NIMBUS technology.
- Penetration of the antimicrobial textiles market with Stay Fresh formulation.
- Development of advanced skin therapy products with MultiStat technology.
- Strategic partnerships with larger industry players for commercialization.
Risiken
- Intense competition from larger pharmaceutical and healthcare companies.
- Stringent regulatory requirements and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
- Potential for technological obsolescence.
Wettbewerbsvorteile
- Proprietary Technologies: Patented NIMBUS, Stay Fresh, and MultiStat technologies provide a competitive edge.
- Specialized Expertise: Focus on antimicrobial and hemostatic solutions creates a niche market position.
- Established Relationships: Existing relationships with government agencies and healthcare providers offer a stable customer base.
Ueber QMDT
Founded in 1997 and headquartered in Gainesville, Florida, Quick-Med Technologies, Inc. is a life sciences company dedicated to the research, development, and commercialization of proprietary technologies aimed at the medical and consumer healthcare markets. The company specializes in creating innovative biomedical products and devices with a focus on antibacterial applications. Quick-Med's core technologies include the Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers exhibiting antimicrobial and hemostatic properties suitable for various applications. Additionally, they offer Stay Fresh, a chemical formulation designed for textiles, providing durable antimicrobial protection against a broad spectrum of bacteria. Their MultiStat technology represents a collection of patented methods and compounds geared towards advanced skin therapy applications. Quick-Med Technologies serves a diverse clientele, including government agencies, healthcare and medical organizations, apparel and textile manufacturers, and personal care companies, providing them with specialized solutions based on their unique technology platforms. The company's focus on innovation and specialized applications positions it within the niche market of advanced antimicrobial and hemostatic technologies.
Was das Unternehmen tut
- Develop proprietary antimicrobial technologies.
- Create hemostatic products for medical applications.
- Formulate antimicrobial solutions for textiles.
- Research and develop skin therapy products.
- Serve government agencies with specialized solutions.
- Cater to healthcare and medical companies.
- Provide solutions for the apparel and textile industry.
- Offer products for the personal care market.
Geschaeftsmodell
- Develop and patent proprietary technologies in the antimicrobial and hemostatic fields.
- Commercialize these technologies through direct sales to government agencies and healthcare providers.
- License technologies to companies in the textile and personal care industries.
- Generate revenue through product sales, licensing fees, and royalty agreements.
Branchenkontext
Quick-Med Technologies operates within the specialty and generic drug manufacturing industry, characterized by intense competition and stringent regulatory requirements. The market is driven by an increasing demand for advanced antimicrobial and hemostatic solutions across healthcare, textiles, and personal care sectors. Companies like Quick-Med differentiate themselves through proprietary technologies and specialized applications. The industry is subject to evolving regulatory standards and pricing pressures, requiring companies to continuously innovate and adapt to maintain competitiveness. The overall drug manufacturing industry is projected to grow, driven by aging populations and increasing healthcare expenditure.
Wichtige Kunden
- Government agencies requiring antimicrobial solutions.
- Healthcare and medical companies seeking advanced wound care products.
- Apparel and textile manufacturers looking for antimicrobial fabrics.
- Personal care companies developing skin therapy products.
Finanzdaten
Chart & Info
Quick-Med Technologies, Inc. (QMDT) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer QMDT.
Kursziele
Wall-Street-Kurszielanalyse fuer QMDT.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von QMDT auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Gregory S. Schultz
CEO
Gregory S. Schultz serves as the CEO of Quick-Med Technologies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the development and commercialization of the company's proprietary technologies in the medical and consumer healthcare markets. His leadership is crucial for navigating the challenges of a small company operating in a competitive industry.
Erfolgsbilanz: Under Gregory S. Schultz's leadership, Quick-Med Technologies has focused on developing and patenting its core technologies, including NIMBUS, Stay Fresh, and MultiStat. Key milestones include securing government contracts and establishing relationships with healthcare providers. The company has also focused on exploring licensing opportunities to expand its market reach.
QMDT OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quick-Med Technologies may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. This tier contrasts sharply with exchanges like NYSE or NASDAQ, which have much stricter listing requirements.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial information and regulatory oversight.
- Price Volatility: Potential for significant price swings due to speculative trading.
- Dilution Risk: Potential for the company to issue new shares, diluting existing shareholders' ownership.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial losses.
- Verify the company's financial statements and SEC filings (if any).
- Research the backgrounds of the company's management team and board members.
- Assess the company's intellectual property and patent portfolio.
- Evaluate the company's competitive landscape and market position.
- Understand the company's business model and revenue streams.
- Determine if the company is subject to any regulatory investigations or legal proceedings.
- Consult with a qualified financial advisor before investing.
- Patented Technologies: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Government Contracts: Existing relationships with government agencies.
- Scientific Publications: Peer-reviewed publications supporting the efficacy of their technologies.
QMDT Healthcare Aktien-FAQ
What are the key factors to evaluate for QMDT?
Quick-Med Technologies, Inc. (QMDT) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Primary risk to monitor: Ongoing: Limited financial resources and negative profitability.. This is not financial advice.
How frequently does QMDT data refresh on this page?
QMDT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven QMDT's recent stock price performance?
Recent price movement in Quick-Med Technologies, Inc. (QMDT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider QMDT overvalued or undervalued right now?
Determining whether Quick-Med Technologies, Inc. (QMDT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying QMDT?
Before investing in Quick-Med Technologies, Inc. (QMDT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding QMDT to a portfolio?
Potential reasons to consider Quick-Med Technologies, Inc. (QMDT) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Additionally: Potential for diverse applications in healthcare, textiles, and personal care.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of QMDT?
Yes, most major brokerages offer fractional shares of Quick-Med Technologies, Inc. (QMDT) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track QMDT's earnings and financial reports?
Quick-Med Technologies, Inc. (QMDT) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for QMDT earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available for OTC-listed companies.
- Financial data based on available public information.